© 2020 MJH Life Sciences™ and . All rights reserved.
March 15, 2017
As we learn more about the biology of AML, it appears that 7+3 only rarely clears residual leukemic clones in patients with higher-risk disease. New therapies are needed that can target and eradicate resistant subclones early in the disease course.